You are here

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

Last updated on November 21, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35235 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postoperative Pain, Inguinal Hernia
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
17-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- The subject will have elective ( the subject chooses, but does not have to undergo
surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair),
using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl
or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus
local anesthetic infiltration at the conclusion of surgery. Study surgery should be
anticipated to be in the morning.

- Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such
as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control
after surgery.

- The subject will be available for a visit within 72 hours of the day of surgery if
not admitted the night before for baseline assessments before taking any study
medication, and then to receive study medication prior to the day before surgery.

- The subject is expected and agrees to remain at the hospital (or intermediate care
facility) for a minimum of 3 hours following surgery.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with non elective or emergency surgery (must have the surgery no matter
what), or hernia with incarceration (the trapping of abdominal contents within the
hernia itself).

- Subjects with hernia repair that is not a primary repair. The planned use of nerve
block or spinal/epidural/paravertebral anesthesia or surgery is not planned with
general anesthesia.

- Subjects that are not allowed to receive the anesthesia agents indicated per protocol
and general anesthesia.

NCT00551135
Pfizer
Completed
Surgical Pain After Inguinal Hernia Repair (SPAIHR)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Surgical Pain After Inguinal Hernia Repair (SPAIHR)
Official Title  ICMJE A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
Brief SummaryThe purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Pain, Postoperative
  • Hernia, Inguinal
Intervention  ICMJE
  • Drug: Pregabalin
    150 mg BID
  • Drug: placebo
    Placebo
  • Drug: Pregabalin
    75 mg BID
  • Drug: Pregabalin
    25 mg BID
Study Arms  ICMJE
  • Experimental: 3
    Intervention: Drug: Pregabalin
  • Placebo Comparator: 4
    Intervention: Drug: placebo
  • Experimental: 2
    Intervention: Drug: Pregabalin
  • Experimental: 1
    Intervention: Drug: Pregabalin
Publications *Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 25, 2010)
425
Original Enrollment  ICMJE
 (submitted: October 26, 2007)
400
Actual Study Completion Date  ICMJE September 2009
Actual Primary Completion DateJune 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • The subject will have elective ( the subject chooses, but does not have to undergo surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. Study surgery should be anticipated to be in the morning.
  • Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.
  • The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.
  • The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.

Exclusion Criteria:

  • Subjects with non elective or emergency surgery (must have the surgery no matter what), or hernia with incarceration (the trapping of abdominal contents within the hernia itself).
  • Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.
  • Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 17 Years to 75 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   India,   Spain,   Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00551135
Other Study ID Numbers  ICMJE A0081171
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trials Disclosure Group, Pfizer, Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJune 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now